WallStSmart

AbbVie Inc (ABBV)vsJIN MEDICAL INTERNATIONAL LTD. Ordinary Shares (ZJYL)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

AbbVie Inc generates 334568% more annual revenue ($66.01B vs $19.73M). ABBV leads profitability with a 15.7% profit margin vs 6.0%. ZJYL trades at a lower P/E of 20.8x. ABBV earns a higher WallStSmart Score of 77/100 (B+).

ABBV

Strong Buy

77

out of 100

Grade: B+

Growth: 6.7Profit: 9.0Value: 4.0Quality: 5.0
Piotroski: 5/9Altman Z: 0.40

ZJYL

Avoid

15

out of 100

Grade: F

Growth: 2.7Profit: 3.5Value: 5.3Quality: 5.5
Piotroski: 1/9Altman Z: 2.18
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABBVSignificantly Overvalued (-79.8%)

Margin of Safety

-79.8%

Fair Value

$157.70

Current Price

$286.20

$128.50 premium

UndervaluedFair: $157.70Overvalued

Intrinsic value data unavailable for ZJYL.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABBV6 strengths · Avg: 9.7/10
Market CapQuality
$520.47B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
62.3%10/10

Every $100 of equity generates 62 in profit

Operating MarginProfitability
36.6%10/10

Strong operational efficiency at 36.6%

EPS GrowthGrowth
2282.0%10/10

Earnings expanding 2282.0% YoY

Debt/EquityHealth
-17.6510/10

Conservative balance sheet, low leverage

PEG RatioValuation
0.598/10

Growing faster than its price suggests

ZJYL1 strengths · Avg: 10.0/10
Price/BookValuation
0.9x10/10

Reasonable price relative to book value

Areas to Watch

ABBV2 concerns · Avg: 2.0/10
P/E RatioValuation
50.6x2/10

Premium valuation, high expectations priced in

Altman Z-ScoreHealth
0.402/10

Distress zone — elevated risk

ZJYL4 concerns · Avg: 3.0/10
Market CapQuality
$628.82M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
3.4%3/10

ROE of 3.4% — below average capital efficiency

Profit MarginProfitability
6.0%3/10

6.0% margin — thin

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : ABBV

The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 15.7% and operating margin at 36.6%. Revenue growth of 10.3% demonstrates continued momentum.

Bull Case : ZJYL

The strongest argument for ZJYL centers on Price/Book.

Bear Case : ABBV

The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 50.6x leaves little room for execution misses.

Bear Case : ZJYL

The primary concerns for ZJYL are Market Cap, Return on Equity, Profit Margin.

Key Dynamics to Monitor

ABBV profiles as a mature stock while ZJYL is a value play — different risk/reward profiles.

ZJYL carries more volatility with a beta of 7.32 — expect wider price swings.

ABBV is growing revenue faster at 10.3% — sustainability is the question.

ABBV generates stronger free cash flow (7.3B), providing more financial flexibility.

Bottom Line

ABBV scores higher overall (77/100 vs 15/100), backed by strong 15.7% margins and 10.3% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

AbbVie Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.

JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Jin Medical International Ltd. designs and manufactures wheelchairs and living aids products.

Want to dig deeper into these stocks?